enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene-based immunotherapy company, today reported the grant of inducem...
Will the option grants have any impact on the company’s compliance with NASDAQ Listing Rule 5635(c)(4) or other regulatory considerations?
How might the market perceive the grant of non‑qualified stock options—does it suggest confidence in future valuation growth?
What is the likelihood that the option holders will exercise and sell shares in the near term, potentially adding selling pressure?
19 days ago